FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.

导出 OA

翻译打印收藏纠错

作者： Filippo,Pietrantonio ^[1] ; Giovanni,Fucà ^[2] ; Daniele,Rossini ^[1] ; Hans-Joachim,Schmoll ^[3] ; Johanna C,Bendell ^[4] ; Federica,Morano ^[5] ; Carlotta,Antoniotti ^[6] ; Salvatore,Corallo ^[1] ; Beatrice,Borelli ^[3] ; Alessandra,Raimondi ^[4] ; Federica,Marmorino ^[1] ; Monica,Niger ^[3] ; Alessandra,Boccaccino ^[4] ; Gianluca,Masi ^[1] ; Sara,Lonardi ^[3] ; Luca,Boni ^[4] ; Filippo,de Braud ^[1] ; Maria,Di Bartolomeo ^[3] ; Alfredo,Falcone ^[4] ; Chiara,Cremolini ^[3]

作者单位： Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. ^[1] Oncology and Hemato-oncology Department, University of Milan, Milan, Italy. ^[2] Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. ^[3] Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. ^[4] Klinik fur Innere Med IV, University Clinic Halle, Halle, Germany. ^[5] GI Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, USA. ^[6] Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy. ^[7] Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. ^[8]

关键词 Bevacizumab Combination chemotherapy FOLFOX FOLFOXIRI Metastatic colorectal cancer Panitumumab